Rheumatoid Arthritis Treatment Guidelines

Initial Treatment Strategy

The American College of Rheumatology recommends starting methotrexate (MTX) immediately as first-line therapy for all patients with newly diagnosed rheumatoid arthritis, aiming for a treatment target of remission or low disease activity 1, 2, 3
Methotrexate is the preferred initial DMARD for both early RA (disease duration <6 months) and established RA (disease duration ≥6 months) 1, 3
The European League Against Rheumatism recommends starting DMARD therapy as soon as the diagnosis of RA is made—do not delay treatment 2
If MTX is contraindicated or not tolerated early, use sulfasalazine or leflunomide as alternatives 2

Add low-dose glucocorticoids (≤10 mg/day prednisone equivalent) for patients with moderate or high disease activity when starting DMARDs 1, 3
Use glucocorticoids for the shortest duration possible (<3 months) as "bridge therapy" until DMARDs take effect 1, 2
Taper glucocorticoids as rapidly as clinically feasible to minimize long-term toxicity 2

Monitor disease activity every 1-3 months in patients with active disease 2
If no improvement by 3 months after starting treatment, adjust therapy 2
If treatment target (remission or low disease activity) not reached by 6 months, therapy must be adjusted 2

Add biologic therapy for patients with moderate to severely active RA who have inadequate response to MTX and/or other csDMARDs 1, 4
Biologic therapy should be used in combination with MTX when possible, as this combination is superior to biologic monotherapy 1, 3
The following biologics are appropriate first-line options (in combination with MTX): TNF inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) 2

The treatment target should be remission or low disease activity 1, 3
Use a targeted approach (adjusting therapy based on disease activity measures) rather than a non-targeted approach 1
Disease activity should be assessed using standardized measures: SDAI >11 or CDAI >10 indicates moderate disease activity requiring treatment intensification 4

If patient achieves persistent remission after tapering glucocorticoids, consider tapering biologic DMARDs, especially if combined with a csDMARD 2
In cases of sustained long-term remission (≥1 year), cautious reduction of csDMARD dose may be considered 2, 5

Do not delay DMARD initiation—early treatment with DMARDs is associated with better long-term outcomes and reduced joint damage 1, 3
Do not use biologic monotherapy when MTX can be combined—combination therapy is more effective 1
Do not continue long-term glucocorticoids—use only as short-term bridge therapy due to lack of long-term safety data 1, 3